Synbiotic mixture
US-9005682-B2 · Apr 14, 2015 · US
US10918653B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10918653-B2 |
| Application number | US-201916667196-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 29, 2019 |
| Priority date | Jul 12, 2010 |
| Publication date | Feb 16, 2021 |
| Grant date | Feb 16, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.
Opening claim text (preview).
What is claimed is: 1. A method of treating gastrointestinal tract microbiota imbalances in an infant, wherein the method comprises administering to the infant a sufficient amount of a composition of Bifidobacterium subsp. infantis or B. breve in or in conjunction with an infant formula, wherein the infant formula comprises one or more of the following fucosylated oligosaccharides as found in bovine milk: an oligosaccharide consisting of 3 Hexose (Hex) moieties, 4 n-acetyl hexosamine (HexNAc) moieties and 1 fucose (Fuc) moiety; an oligosaccharide consisting of 4 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety; an oligosaccharide consisting of 3 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety; an oligosaccharide consisting of 5 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety; an oligosaccharide consisting of 4 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety; and an oligosaccharide consisting of 3 Hex moieties, 6 HexNAc moieties, and 1 Fuc moiety; and wherein the composition stimulates the production of a bifidobacterial secretion that reduces colonization of enteropathogenic bacteria in the gut of the infant; modulates signals generated by enteroendocrine and gut epithelial cells in the infant; improves at least one biomarker of gut health in the infant; and/or increases gut colonization and persistence of probiotic bacteria in the infant gut. 2. The method of claim 1 wherein the infant formula further comprises one or more oligosaccharides comprising 2 hexose (Hex) moieties and 1 fucose (Fuc) moiety; 4 Hex moieties and 1 Fuc moiety; 2 HEX moieties, 1 n-acetyl hexosamine (HexNAc) moiety and 1 Fuc moiety; 3 Hex moieties and 1 HexNAc moiety; 3 Hex moieties and 6 HexNAc moieties; 4 Hex moieties and 3 HexNAc moieties; 3 Hex moieties and 4 HexNAc moieties; 6 Hex moieties and 2 HexNAc moieties; 4 Hex moieties and 4 HexNAc moieties; 3 Hex moieties and 5 HexNAc moieties; 5 Hex moieties and 4 HexNAc moieties; or 4 Hex moieties and 5 HexNAc moieties. 3. The method of claim 1 wherein one or more fucosylated oligosaccharide are administered in an amount from 0.001-100 g/L. 4. The method of claim 1 , wherein the composition is administered to an infant at higher risk than the general infant population for the presence of one or more enteropathogenic bacteria or inflammation. 5. The method of claim 4 , wherein the infant is a premature infant or an infant in gastrointestinal distress. 6. The method of claim 4 , wherein the composition reduces the colonization of the infant gut by one of more enteropathogenic bacteria selected from the group: Clostridium difficile, Clostridium perfringens, Salmonella enterica, Salmonella typhimurium, Vibrio cholerae, E. coli O157:H7, Listeria monocytogenes, Yersinia enterocolitis, Enterococcus faecalis , and/or Shigella sp. 7. The method of claim 1 , wherein the composition is administered to an infant at higher risk than the general population for necrotizing enterocolitis. 8. The method of claim 1 , wherein the one or more fucosylated oligosaccharides promotes the growth of the Bifidobacterium subsp. infantis thereby promoting protection and/or clearance of infection. 9. The method of claim 8 , wherein the composition prevents necrotizing enterocolitis. 10. The method of claim 1 , wherein the infant formula further comprises synthetic 2′-and/or 3′-Fucosyllactose. 11. The method of claim 1 , wherein the infant formula further comprises a synthetic oligosaccharide comprising 3 Hex and 1 HexNAc.
produced by the action of a carbohydrase {(EC 3.2.x)}, e.g. by alpha-amylase {, e.g. by cellulase, hemicellulase} · CPC title
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title
Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737) · CPC title
containing two or more polymers of the same C08L -group · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.